Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Operating Expenses (2021 - 2025)

Lyra Therapeutics has reported Operating Expenses over the past 5 years, most recently at $7.1 million for Q4 2025.

  • Quarterly results put Operating Expenses at $7.1 million for Q4 2025, down 38.67% from a year ago — trailing twelve months through Dec 2025 was $31.4 million (down 67.9% YoY), and the annual figure for FY2025 was $31.4 million, down 67.9%.
  • Operating Expenses for Q4 2025 was $7.1 million at Lyra Therapeutics, up from $6.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for LYRA hit a ceiling of $49.6 million in Q2 2024 and a floor of $6.3 million in Q3 2025.
  • Median Operating Expenses over the past 5 years was $13.3 million (2021), compared with a mean of $15.0 million.
  • Biggest five-year swings in Operating Expenses: soared 192.27% in 2024 and later plummeted 81.83% in 2025.
  • Lyra Therapeutics' Operating Expenses stood at $13.9 million in 2021, then increased by 9.04% to $15.2 million in 2022, then grew by 9.61% to $16.6 million in 2023, then crashed by 30.11% to $11.6 million in 2024, then crashed by 38.67% to $7.1 million in 2025.
  • The last three reported values for Operating Expenses were $7.1 million (Q4 2025), $6.3 million (Q3 2025), and $9.0 million (Q2 2025) per Business Quant data.